Permisso Secures $2.8M Seed Round

Predictheon

Predictheon started in 2015 when a group of medical doctors, anesthesiologists to be specific, together with math modelers, and computer engineers decided to move forward their prior research track. The original goal was to create a new concept in patient care management, one that seeks to integrate predictive analytics with real-time monitoring, in order to give clinicians meaningful information about a patient’s future behavior. Such information would allow an anesthesia provider to anticipate a clinically significant change, or possibly an upcoming negative event before it occurs. This concept arose from the desire to better understand how the current state of the patient will change in the next 5 or 10 minutes from now, allowing the anesthesia provider to proactively act ahead of time, to prevent a potentially severe adverse side effect before it happens. The concept expanded to other areas of healthcare where we are actively searching for predictive solutions (perioperative blood management, altered postoperative cognition, critical care, oncology, …). Predictheon was created as a company in 2019. We verified our idea by continuously collecting "outcome-oriented" high-resolution data from a vast number of patients, analyzing those data under a population perspective, using classical modeling or AI-derived methods, and have now come up with a powerful “predictive engine” based on mathematical models describing the relations between patients and outcomes. When we apply our unique solution to a new patient, our models can predict future behavior, including potentially severe side effects before they happen. Predictheon's individualized patient care now results in optimal decision making and increased patient safety during a medical procedure that requires the patient to have sedation or general anesthesia and will expand into other areas of patient care.

BlueWalker Capital

BlueWalker Capital is a hedge fund developing systematic and quantitative trading strategies native to prediction markets. We log hundreds of millions of trades and order book ticks per day, isolate market pairs from tens of millions of combinations, and continuously monitor for a range of arbitrage opportunities we execute on. We trade algorithmically using our own balance sheet, generating daily returns exceeding 1% with the capacity to rotate hundreds of thousands of euros in daily volume. Our mission is to become the leading hedge fund in this emerging asset class, delivering investment returns while making prediction markets efficient as the world's most accurate source of truth.

Luxquanta

Luxquanta was established as a spin-off from ICFO in May 2021 with the goal of integrating advanced and secure quantum cryptography technologies into conventional communication infrastructures. The company is driven by a passion for innovation and a deep commitment to delivering state-of-the-art Quantum Key Distribution solutions that are easy to install while meeting the highest security requirements of governmental institutions, financial entities, data centres, and private telecommunication network providers. With its cutting-edge technology, experienced team, and dedication to excellence, LuxQuanta is determined to shape the future of quantum-secured communications, while nurturing the development of a robust quantum ecosystem in Europe.

INCAPTO

INCAPTO nació en 2020 con una misión: acabar con las cápsulas y el café torrefacto y descubrir a las personas que toman café que existe una mejor manera de hacerlo. Fundada por Francesc Font, Bea Mesas y Joaquim Mach, que unieron sus fuerzas para ofrecer una alternativa real al café en cápsulas, consiguiendo una experiencia de café de calidad, funcional, económica y sostenible. No somos una marca de café más. Hemos llegado para cambiar las reglas del juego y crear un mundo del café más justo, más responsable y con mejor sabor. En INCAPTO ya hemos dado el primer paso. Tenemos la seguridad de que disfrutar de un café de calidad, más sostenible y más justo con las personas que lo cultivan, es posible. Por eso, hemos creado una solución de café en grano de especialidad y cafeteras superautomáticas que muelen al instante, ofreciendo comodidad y calidad, sin generar residuos innecesarios.

BASE4 Biosciences

BASE4 Biosciences is a precision health company building a new layer for preventive medicine. Using a single blood sample and AI-driven transcriptomic analysis, we infer the functional health and biological age of 47+ tissues, enabling early detection of organ-level deterioration before clinical symptoms appear. Our platform combines multi-omics data and proprietary models to deliver personalized, explainable insights into disease risk, identifying the molecular pathways driving decline. Initially focused on women’s health, BASE4 aims to transform healthcare from reactive to predictive, enabling earlier intervention, better outcomes, and continuous health monitoring.